Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.
Zaccarelli, M., Perno, C.f., Forbici, F., Soldani, F., Bonfigli, S., Gori, C., et al. (2004). Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. CLINICAL INFECTIOUS DISEASES, 38(3), 433-437 [10.1086/381097].
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy
PERNO, CARLO FEDERICO;Bellocchi, M;
2004-02-01
Abstract
Among 470 patients with acquired immune deficiency syndrome and/or human immunodeficiency virus infection (HIV/AIDS) who underwent genotype resistance testing (GRT) after the failure of therapy, 17 (3.6%) harbored the Q151M mutation. The Q151M mutation was associated with younger age, lower CD4(+) lymphocyte count, higher HIV RNA level, and treatment with >2 pre-GRT regimens. By contrast, the Q151M mutation was inversely associated with lamivudine administration. A full reversion of the Q151M mutation was observed in 5 of 5 patients who underwent treatment interruption after GRT. The reversion was followed by a response to salvage therapy in 4 (80%) of 5 patients.Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
